These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 16556152)

  • 21. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy.
    Gonzalez Molina M; Seron D; Garcia del Moral R; Carrera M; Sola E; Jesus Alferez M; Gomez Ullate P; Capdevila L; Gentil MA
    Transplantation; 2004 Jan; 77(2):215-20. PubMed ID: 14742984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of cyclosporine withdrawal on living related renal transplants: a single-center experience.
    Jha V; Muthukumar T; Kohli HS; Sud K; Gupta KL; Sakhuja V
    Am J Kidney Dis; 2001 Jan; 37(1):119-124. PubMed ID: 11136176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
    Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
    J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine.
    Sanchez V; Delgado JF; Morales JM; Tello R; Gómez MA; Escribano P; de la Cámara AG; de la Calzada CS
    Transplant Proc; 2004 Nov; 36(9):2823-5. PubMed ID: 15621159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion of azathioprine to mycophenolate mofetil and chronic graft failure progression.
    Lezaic VD; Marinkovic J; Ristic S; Dokic ZM; Basta Jovanovic G; Radivojevic DM; Blagojevic RN; Djukanovic LD
    Transplant Proc; 2005 Mar; 37(2):734-6. PubMed ID: 15848517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
    Attallah N; Goggins M; Nori U; Abouljoud M; Zasuwa G; Venkat KK; Parasuraman R
    Transplant Proc; 2005 Jun; 37(5):2060-2. PubMed ID: 15964338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful reversal of acute vascular rejection and cyclosporine-associated nephrotoxicity in renal allograft with combined sirolimus and mycophenolate mofetil as immunotherapy.
    Ołdakowska-Jedynak U; Paczek L; Mucha K; Foroncewicz B; Perkowska-Ptasińska A
    Transplant Proc; 2006; 38(1):66-8. PubMed ID: 16504666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steroid withdrawal in kidney transplant recipients: is it a safe option?
    Sanfey H; Haussman G; Isaacs I; Ishitani M; Lobo P; McCullough C; Pruett T
    Clin Transplant; 1997 Oct; 11(5 Pt 2):500-4. PubMed ID: 9361950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
    Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
    Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppression in live-related donor renal transplantation.
    Iman A; Rao M; Juneja R; Jacob CK
    Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
    Lou HX; Vathsala A
    Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients.
    Nart A; Sipahi S; Aykas A; Uslu A; Hoşcoşkun C; Toz H
    Transplant Proc; 2008; 40(1):189-92. PubMed ID: 18261583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombotic microangiopathy in marginal kidneys after sirolimus use.
    Pellé G; Xu Y; Khoury N; Mougenot B; Rondeau E
    Am J Kidney Dis; 2005 Dec; 46(6):1124-8. PubMed ID: 16310579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.